Targeted antiretroviral therapy for human immunodeficiency virus treatment is important. Therefore, this study provides evidence on patient preferences for current and novel long-acting antiretroviral therapy attributes.

Based on a discrete choice experiment, the frequency of dosing (36.1%) and the risk of long-term side effects (28.2%) were most important for patients. The latent class analysis demonstrated significant differences between two patient groups; while the first class found the frequency of dosing (44.1%) to be most important, the second group focused on the risk of long-term side effects (50.3%).

The results may inform policymakers, physicians, research institutions, and other stakeholders about patients’ preferences of novel long-acting antiretroviral therapies for human immunodeficiency virus treatment.